Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-07: Tiragolumab + Atezolizumab in Esophageal Squamous Cell Carcinoma
NCT04543617Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab and atezolizumab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Roche. Primary endpoints: Progression-Free Survival and Overall Survival. Started Sep 2020; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04543617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543617.